S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:AXGN

AxoGen Stock Forecast, Price & News

$20.30
+0.37 (+1.86 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.70
Now: $20.30
$20.39
50-Day Range
$17.18
MA: $19.58
$22.60
52-Week Range
$7.16
Now: $20.30
$22.89
Volume318,183 shs
Average Volume276,074 shs
Market Capitalization$826.96 million
P/E RatioN/A
Dividend YieldN/A
Beta0.71
AxoGen, Inc., together with its subsidiaries, provides surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
AxoGen logo

Headlines

AxoGen, Inc. to Host Earnings Call - Yahoo Finance
February 22, 2021 |  finance.yahoo.com
AxoGen, Inc. to Host Earnings Call
February 22, 2021 |  finance.yahoo.com
A Preview Of Axogen's Earnings - Yahoo Finance
February 19, 2021 |  finance.yahoo.com
A Preview Of Axogen's Earnings
February 19, 2021 |  benzinga.com
AxoGen, Inc. (NASDAQ:AXGN): Is Breakeven Near?
February 19, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXGN
CUSIPN/A
Phone386-462-6800
Employees371
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$106.71 million
Book Value$3.35 per share

Profitability

Net Income$-29,140,000.00

Miscellaneous

Market Cap$826.96 million
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.50 out of 5 stars

Medical Sector

502nd out of 1,972 stocks

Electromedical Equipment Industry

11th out of 61 stocks

Analyst Opinion: 2.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$20.30
+0.37 (+1.86 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AXGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AxoGen (NASDAQ:AXGN) Frequently Asked Questions

Is AxoGen a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AxoGen stock.
View analyst ratings for AxoGen
or view top-rated stocks.

What stocks does MarketBeat like better than AxoGen?

Wall Street analysts have given AxoGen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AxoGen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is AxoGen's next earnings date?

AxoGen is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for AxoGen
.

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) announced its earnings results on Sunday, February, 21st. The medical equipment provider reported ($0.08) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.16) by $0.08. AxoGen had a negative trailing twelve-month return on equity of 19.83% and a negative net margin of 22.98%.
View AxoGen's earnings history
.

How has AxoGen's stock price been impacted by COVID-19?

AxoGen's stock was trading at $10.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AXGN shares have increased by 89.7% and is now trading at $20.30.
View which stocks have been most impacted by COVID-19
.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $32.4 million, compared to the consensus revenue estimate of $29.52 million.

What price target have analysts set for AXGN?

5 equities research analysts have issued 12 month price targets for AxoGen's shares. Their forecasts range from $21.00 to $27.00. On average, they anticipate AxoGen's share price to reach $23.75 in the next twelve months. This suggests a possible upside of 17.0% from the stock's current price.
View analysts' price targets for AxoGen
or view top-rated stocks among Wall Street analysts.

Who are AxoGen's key executives?

AxoGen's management team includes the following people:
  • Ms. Karen Zaderej, Chairman, Pres & CEO (Age 59, Pay $999.96k)
  • Mr. Peter J. Mariani, Chief Financial Officer (Age 57, Pay $548.03k)
  • Ms. Maria D. Martinez, Chief HR Officer (Age 53, Pay $460.48k)
  • Mr. Angelo G. Scopelianos Ph.D., Chief R&D Officer (Age 65, Pay $554.14k)
  • Mr. Eric A. Sandberg, Chief Commercial Officer (Age 56, Pay $476.8k)
  • Mr. Michael Donovan, VP of Operations (Age 56)
  • Mr. Bradley L. Ottinger, Gen. Counsel & Chief Compliance Officer
  • Mr. Gregory Davault, VP of Marketing (Age 53)
  • Ms. Isabelle Billet, Chief Strategy & Bus. Devel. Officer (Age 59)
  • Mr. David Hansen, VP of Fin. & Treasurer (Age 60)

What is Karen Zaderej's approval rating as AxoGen's CEO?

3 employees have rated AxoGen CEO Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among AxoGen's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of AxoGen's key competitors?

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.40%), Janus Henderson Group PLC (3.71%), William Blair Investment Management LLC (3.33%), Baillie Gifford & Co. (2.86%), Granite Point Capital Management L.P. (1.31%) and Northern Trust Corp (1.12%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Angelo Scopelianos, Daniel Pietrzak, David K Hansen, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Michael Patrick Donovan, Peter J Mariani and Quentin S Blackford.
View institutional ownership trends for AxoGen
.

Which major investors are selling AxoGen stock?

AXGN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Granite Point Capital Management L.P., Renaissance Technologies LLC, Northern Trust Corp, Perkins Capital Management Inc., Wrapmanager Inc., Alliancebernstein L.P., and OLD National Bancorp IN. Company insiders that have sold AxoGen company stock in the last year include Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Michael Patrick Donovan, and Peter J Mariani.
View insider buying and selling activity for AxoGen
or view top insider-selling stocks.

Which major investors are buying AxoGen stock?

AXGN stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, JPMorgan Chase & Co., BlackRock Inc., William Blair Investment Management LLC, Baillie Gifford & Co., Calamos Advisors LLC, Russell Investments Group Ltd., and Exchange Traded Concepts LLC. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, Daniel Pietrzak, Isabelle Billet, Karen L Zaderej, and Quentin S Blackford.
View insider buying and selling activity for AxoGen
or or view top insider-buying stocks.

How do I buy shares of AxoGen?

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $20.30.

How much money does AxoGen make?

AxoGen has a market capitalization of $826.96 million and generates $106.71 million in revenue each year. The medical equipment provider earns $-29,140,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

How many employees does AxoGen have?

AxoGen employs 371 workers across the globe.

What is AxoGen's official website?

The official website for AxoGen is www.axogeninc.com.

Where are AxoGen's headquarters?

AxoGen is headquartered at 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.